Effects of MK-7 supplementation on glycemic status, anthropometric indices and lipid profile in patients with type 2 diabetes: A randomized controlled trial

Nahid Karamzad, Esmaeil Faraji, Shaghayegh Adeli, Kristin Carson-Chahhoud, Samaneh Azizi, Bahram Pourghassem Gargari

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background: Type 2 diabetes mellitus (T2DM) is a prevalent disorder which accounts for 90–95% of diabetic patients. The aim of this study was to assess the effects of menaquinone (MK-7) supplementation on glycemic indices, anthropometric indices and lipid profile, among patients with T2DM. Methods: In this double-blind placebo-controlled randomized clinical trial, 60 men and women with T2DM were allocated equally into either the MK-7 (200 µg/day) or the placebo group. Physical activity level and dietary intake were assessed using the international physical activity questionnaire-short form (IPAQ-SF) and a 3-day food record, pre-and post-intervention. Anthropometric measures, blood pressure, glycemic indices and lipid profile including fasting blood sugar (FBS), hemoglobin A1c (HBA1C), fasting insulin (FI), homeostatic model assessment insulin resistance index (HOMA-IR), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were measured at baseline and after twelve weeks. Results: Forty-five patients completed the trial. There were no significant between-group differences for calorie intake, macronutrient intake, physical activity level or anthropometric measures at baseline and at the end of the study. Dietary vitamin K intake increased significantly at the end of the study in the MK-7 (p: 0.02) and placebo (p: 0.001) groups, but intergroup differences were not significant (p: 0.86). FBS (p: 0.01), HbA1c (p: 0.002), fasting insulin (p: 0.01) and HOMA-IR (p: 0.007) decreased significantly in the MK-7 group. Furthermore, after adjustment for the baseline values and changes of vitamin K intake at the end of study, FBS and HbA1C showed significant intergroup changes, and they were significantly lower in the MK-7 group compared to the placebo group. Lipid profile (TG, TC, LDL-C, HDL-C and LDL-C/HDL-C) did not change significantly within or between groups. Conclusion: MK-7 supplementation seems to be effective in the improvement of glycemic indices, but not the lipid profile of patients with T2DM. Clinical Trial Registration: The present study was prospectively registered at the Iranian Registry of Clinical Trials on May 2019 (ID: IRCT20100123003140N22).

Original languageEnglish
Pages (from-to)2239-2249
Number of pages11
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publication statusPublished or Issued - 2020
Externally publishedYes


  • Anthropometric indices
  • Diabetes
  • Dyslipidemia
  • Glycemic status
  • MK-7
  • Menaquinone
  • Phylloquinone
  • Vitamin K

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology

Cite this